ISSN: 2153-0777

Journal of Bioengineering and Bioelectronics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

Biochips: Bright Future in Clinical Dx?

M. Kohl1, S. Koch2, M. Keller3 and H.P. Deigner1,2*
1Furtwangen University, 78054 Villingen-Schwenningen, Germany
2Fraunhofer Institute IZI, Leipzig/EXIM Rostock, 18057 Rostock, Germany
3Clinics Essen, Centre for Pediatrics, 45147 Essen
Corresponding Author : Dr. Hans-Peter Deigner
Fraunhofer Institut IZI, Leipzig/ EXIM Rostock
18057 Rostock and Furtwangen University
78054 Villingen- Schwenningen, Germany
E-mail: deigner@gmx.de
Received September 10, 2010; Accepted September 10, 2011; Published October 29, 2011
Citation: Kohl M, Koch S, Keller M, Deigner HP (2011) Biochips: Bright Future in Clinical Dx? J Biochip Tissue chip S1:003. doi: 10.4172/2153-0777.S1-e003
Copyright: © 2011 Kohl M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Biochips play an established important role in research on disease biology and systems biology while an increasing number of clinical applications is emerging. What about the future of biochips in medical routine? The term biochip as used by us in this editorial is confined to chips in DNA/RNA analysis, just for sake of brevity, not implying any judgement. We hypothesize that the future will bring a routine use of biochips in diagnostics and provide arguments to support our view. We comment on technological and data analysis aspects, also with regard to 3rd generation sequencing, and point out remaining challenges. We foresee an increasing application of biochips in the clinic and beyond, in the hand of practitioners. What are the reasons to justify the optimism about biochips potential to accelerate not only the understanding of the biological basis of diseases but to develop into an integral part of medicinal diagnostics.

Top